Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway

Zhang,Zhenbo; Zhu,Yaping; Lai,Yunli; Wu,Xiaomei; Feng,Zhengzhong; Yu,Yinhua; Bast,Robert   C.; Wan,Xiaoping; Xi,Xiaowei; Feng,Youji

doi:10.3892/ijo.2013.2054

Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway

Authors:
- Zhenbo Zhang
- Yaping Zhu
- Yunli Lai
- Xiaomei Wu
- Zhengzhong Feng
- Yinhua Yu
- Robert C. Bast
- Xiaoping Wan
- Xiaowei Xi
- Youji Feng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, P.R. China, Department of Biochemistry and Molecular Biology, Guangxi Medical University, Nanning, P.R. China, Department of Pathology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, P.R. China, Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
Published online on: August 6, 2013 https://doi.org/10.3892/ijo.2013.2054
Pages: 1194-1204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

OCT4, a stem cell marker, is overexpressed in several types of human cancer and can induce resistance to chemotherapy and inhibition of apoptosis. We previously demonstrated that human follicle stimulating hormone (FSH) can inhibit ovarian cancer cell apoptosis. However, the role of OCT4 in FSH-induced inhibition of apoptosis has not been reported in detail. Here, we profiled OCT4 protein expression in ovarian epithelial cancer (OEC) with benign cystadenoma, borderline tumor and carcinoma tissues as well as different ovarian cancer cell lines and normal ovarian epithelial cells. Furthermore, the effects of FSH on OCT4 expression and related signaling pathways were evaluated. The overexpression of OCT4 in ovarian carcinoma and OEC cell lines suggest that OCT4 plays a critical role in OEC carcinogenesis. Moreover, FSH-induced apoptosis inhibition was confirmed and FSH stimulation induced the expansion of CD44+CD117+ cells with a stem cell-like phenotype. Re-expression of OCT4 enhanced the expression of Notch, Sox2 and Nanog molecules that play critical roles in cancer stem cell proliferation and differentiation. FSH upregulated the expression of Notch, Sox2 and Nanog and these effects were abolished by knocking down OCT4, suggesting that several cancer stem cell pathways are involved in FSH regulation. We also examined OCT4 expression in surgical specimens of ovarian cancer. Immunohistostaining revealed that OCT4 expression was increased in ovarian carcinoma compared with benign cystadenomas and borderline tumors, and OCT4 expression was significantly correlated with histological grade. Staining for OCT4 was increased in serous cystadenocarcinoma, when compared with clear cell carcinoma. In summary, the OCT4 cancer stem cell signaling pathway may mediate FSH-induced inhibition of apoptosis and could provide a target for treatment of ovarian cancer.

View Figures

View References

1.	Huang Y, Jin H, Liu Y, et al: FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Gu G, Yuan J, Wills M and Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Karoubi G, Gugger M, Schmid R and Dutly A: OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg. 8:393–397. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Atlasi Y, Mowla SJ, Ziaee SA and Bahrami AR: OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 120:1598–1602. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Ezeh UI, Turek PJ, Reijo RA and Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 104:2255–2265. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Shin S, Mitalipova M, Noggle S, et al: Long-term proliferation of human embryonic stem cell-derived neuroepithelial cells using defined adherent culture conditions. Stem Cells. 24:125–138. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 26:495–502. 2005.PubMed/NCBI
8.	Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Chiou SH, Wang ML, Chou YT, et al: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Hu T, Liu S, Breiter DR, Wang F, Tang Y and Sun S: Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Asselin-Labat ML, Vaillant F, Sheridan JM, et al: Control of mammary stem cell function by steroid hormone signalling. Nature. 465:798–802. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Joshi PA, Jackson HW, Beristain AG, et al: Progesterone induces adult mammary stem cell expansion. Nature. 465:803–807. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Baba T, Convery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133⁺ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Ferrandina G, Bonanno G, Pierelli L, et al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 18:506–514. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 27:2875–2883. 2009.PubMed/NCBI
17.	Alvero AB, Chen R, Fu HH, et al: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 8:158–166. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Dou J, Jiang C, Wang J, et al: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int. 35:227–234. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Gao Q, Geng L, Kvalheim G, Gaudernack G and Suo Z: Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol. 33:175–181. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Chen X, Zhang Z, Feng Y, et al: Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol. 22:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Ji Q, Liu PI, Chen PK and Aoyama C: Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer. 112:803–814. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Zhang Z, Jia L, Feng Y and Zheng W: Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett. 278:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Liu D, Zhou P, Zhang L, Wu G, Zheng Y and He F: Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 32:941–950. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Iki K and Pour PM: Expression of Oct4, a stem cell marker, in the hamster pancreatic cancer model. Pancreatology. 6:406–413. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Wang XQ, Ongkeko WM, Chen L, et al: Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Venn A, Watson L, Bruinsma F, Giles G and Healy D: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 354:1586–1590. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Brekelmans CT: Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol. 15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Tavani A, Ricci E, La Vecchia C, et al: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
29.	Riman T, Persson I and Nilsson S: Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf). 49:695–707. 1998. View Article : Google Scholar : PubMed/NCBI
30.	Li Y, Ganta S, Cheng C, Craig R, Ganta RR and Freeman LC: FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor. Mol Cell Endocrinol. 267:26–37. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Lau MT, Wong AS and Leung PC: Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology. 151:2985–2993. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Choi JH, Choi KC, Auersperg N and Leung PC: Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 66:3912–3920. 2006. View Article : Google Scholar
33.	Xu H, Wang W, Li C, et al: WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. Cell Res. 19:561–573. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Chen T, Du J and Lu G: Cell growth arrest and apoptosis induced by Oct4 or Nanog knockdown in mouse embryonic stem cells: a possible role of Trp53. Mol Biol Rep. 39:1855–1861. 2012. View Article : Google Scholar : PubMed/NCBI
35.	Qian X, Xi X and Li L: Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 19:126–132. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Zhang Z, Liao H, Chen X, et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol. 155:69–74. 2010. View Article : Google Scholar : PubMed/NCBI